flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 FLOWing with the — NephJC Semaglutide in CKD - The
Description
This will help support patients in achieving their health goals all around
At 13 to 24 months following prescription, participants experienced a 3.8 per cent drop from baseline weight, with those without diabetes seeing even greater reductions of 5.1 per cent
Dehydration is a common but often preventable side effect reported by patients taking semaglutide and other GLP-1 receptor agonists
Filed Under: clinical trials, Drug Discovery, Metabolic disease/endicrinology
People will still have options, Conti added
